Last reviewed · How we verify
QIV-HD
QIV-HD is a high-dose inactivated influenza vaccine that provides enhanced immune protection against four influenza virus strains.
QIV-HD is a high-dose inactivated influenza vaccine that provides enhanced immune protection against four influenza virus strains. Used for Prevention of influenza A and B in adults, particularly older adults (≥65 years).
At a glance
| Generic name | QIV-HD |
|---|---|
| Also known as | High-dose quadrivalent influenza vaccine |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
QIV-HD contains four times the standard antigen dose (60 µg per strain vs. 15 µg in standard-dose QIV) to elicit a stronger humoral and cellular immune response. This higher antigen content is designed to improve immunogenicity and protective efficacy, particularly in older adults and immunocompromised populations who may have diminished responses to standard-dose vaccines.
Approved indications
- Prevention of influenza A and B in adults, particularly older adults (≥65 years)
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
- Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QIV-HD CI brief — competitive landscape report
- QIV-HD updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI